Stockreport

Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF Salt Lake City, UT, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, a [Read more]